Literature DB >> 20128663

Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life.

Michael L Forbes1, Caroline B Hall, Anne Jackson, Anthony S Masaquel, Parthiv J Mahadevia.   

Abstract

OBJECTIVE: This retrospective cohort study compared the total cost of hospitalisation due to respiratory syncytial virus (RSV) lower respiratory tract infection (LRI) during the first year of life between late-preterm (33-36 weeks gestational age [wGA]) and term (≥ 37 wGA) infants. RESEARCH DESIGN AND METHODS: A large national claims database of commercially insured members was examined to identify hospital admissions associated with RSV between January 2003 and June 2007 among infants at high risk for RSV LRI, including late-preterm infants. Hospital use and costs were compared with those of a reference cohort of term infants with RSV.
RESULTS: The cost of hospitalisation for RSV among late-preterm infants with at least one hospital admission associated with RSV (n=173) was twice that of term infants (n=1,983; $20,269 vs. 9,635; p< 0.001). The mean length of stay was also higher (5.3 vs. 3.4 days; p< 0.001). Approximately 21.9% of hospitalisations for late-preterm infants included an intensive care unit admission compared with 9.6% among term infants (p< 0.001). LIMITATIONS: Reliance on ICD-9 codes to identify potential cohort members may result in misclassification and underreporting the cohort size for conditions of interest.
CONCLUSIONS: Hospitalisation costs and length of stay due to RSV LRI were significantly greater among late-preterm infants compared with term infants and higher than general estimates previously reported in the broader paediatric population.

Entities:  

Mesh:

Year:  2010        PMID: 20128663     DOI: 10.3111/13696990903583404

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  10 in total

1.  The cost of hospital care for management of invasive group A streptococcal infections in England.

Authors:  G J Hughes; A J VAN Hoek; S Sriskandan; T L Lamagni
Journal:  Epidemiol Infect       Date:  2014-09-29       Impact factor: 4.434

2.  Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.

Authors:  K K McLaurin; A M Farr; S W Wade; D R Diakun; D L Stewart
Journal:  J Perinatol       Date:  2016-08-04       Impact factor: 2.521

3.  Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.

Authors:  Caroline Amand; Sabine Tong; Alexia Kieffer; Moe H Kyaw
Journal:  BMC Health Serv Res       Date:  2018-04-20       Impact factor: 2.655

4.  Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.

Authors:  Gary M Ginsberg; Eli Somekh; Yechiel Schlesinger
Journal:  Isr J Health Policy Res       Date:  2018-12-17

Review 5.  Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention.

Authors:  Jessie R Groothuis; J Michael Hoopes; Val G Hemming Jessie
Journal:  Adv Ther       Date:  2011-02-04       Impact factor: 3.845

6.  A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.

Authors:  Mina Suh; Naimisha Movva; Lauren C Bylsma; Jon P Fryzek; Christopher B Nelson
Journal:  J Infect Dis       Date:  2022-08-15       Impact factor: 7.759

7.  Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Authors:  Christopher S Ambrose; Evan J Anderson; Eric A F Simões; Xionghua Wu; Hanaa Elhefni; C Lucy Park; Frangiscos Sifakis; Jessie R Groothuis
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

8.  Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes.

Authors:  Kimmie K McLaurin; Archana Chatterjee; Doris Makari
Journal:  Infect Dis Ther       Date:  2015-10-26

9.  Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.

Authors:  Evan J Anderson; Xavier Carbonell-Estrany; Maarten Blanken; Marcello Lanari; Margaret Sheridan-Pereira; Barry Rodgers-Gray; John Fullarton; Elisabeth Rouffiac; Pamela Vo; Gerard Notario; Fiona Campbell; Bosco Paes
Journal:  Pediatr Infect Dis J       Date:  2017-02       Impact factor: 2.129

10.  Comparison of health care resource utilization among preterm and term infants hospitalized with Human Respiratory Syncytial Virus infections: A systematic review and meta-analysis of retrospective cohort studies.

Authors:  Sebastien Kenmoe; Cyprien Kengne-Nde; Abdou Fatawou Modiyinji; Giuseppina La Rosa; Richard Njouom
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.